Ginsenoside Rf

Ginsenoside Rf
Product Name Ginsenoside Rf
CAS No.: 52286-58-5
Catalog No.: CFN99976
Molecular Formula: C42H72O14
Molecular Weight: 801.01 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: Powder
Targets: Bcl-2/Bax | CDK | Caspase | TNF-α | NO | ROS | IL Receptor | NF-kB | P450 (e.g. CYP17) | GABA Receptor | Calcium Channel
Source: The roots of Panax ginseng C. A. Mey.
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price: $188/20mg
Ginsenoside Rf is a trace component of ginseng root, which has antinociception, analgesia, anti-inflammatory, and anti-cancer activities, it induces G2/Mphase cell cycle arrest and apoptosis in human osteosarcoma MG-63 cells through the mitochondrial pathway. Rf can act through a novel G protein-linked receptor in the nervous system by inhibiting N-type Ca2+ channel. Rf significantly reduces the production of IL-1β, IL-6, TNF-α, NO, and ROS, and suppresses TNF-α/LPS-induced NF-κB transcriptional activity.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Kasetsart University2022, ethesis.1144.
  • Wageningen University & Research2018, January 2018
  • Foods.2022, 11(6):882.
  • The Journal of Supercritical Fluids2021, 176:105305.
  • Life Sci.2019, 216:259-270
  • J of Liquid Chromatography & Related Technologies2024, 47(1-5):14-25.
  • ACS Synth Biol.2022, doi: 10.1021.
  • Plants (Basel).2020, 9(11):1535.
  • Separations2021, 8(1), 1.
  • J Pharm Biomed Anal.2024, 241:115990.
  • Ginsenoside Rg2

    Catalog No: CFN99968
    CAS No: 52286-74-5
    Price: $60/20mg
    Ginsenoside Rf

    Catalog No: CFN99976
    CAS No: 52286-58-5
    Price: $188/20mg
    20-O-Glucoginsenoside Rf

    Catalog No: CFN95036
    CAS No: 68406-27-9
    Price: $318/5mg
    (20R)-Ginsenoside Rh1

    Catalog No: CFN92796
    CAS No: 80952-71-2
    Price: $80/20mg
    20R-Ginsenoside Rg2

    Catalog No: CFN90412
    CAS No: 80952-72-3
    Price: $218/20mg
    (20S)-Protopanaxatriol

    Catalog No: CFN90564
    CAS No: 34080-08-5
    Price: $40/20mg
    Ginsenoside Rh1

    Catalog No: CFN99970
    CAS No: 63223-86-9
    Price: $60/20mg
    Notoginsenoside R2

    Catalog No: CFN92364
    CAS No: 80418-25-3
    Price: $158/20mg
    20(R)-Notoginsenoside R2

    Catalog No: CFN93373
    CAS No: 948046-15-9
    Price: Inquiry(manager@chemfaces.com)
    Notoginsenoside T5

    Catalog No: CFN92824
    CAS No: 769932-34-5
    Price: Inquiry(manager@chemfaces.com)
    Oncol Rep. 2014 Jan;31(1):305-13.
    Induction of G2/M phase cell cycle arrest and apoptosis by ginsenoside Rf in human osteosarcoma MG‑63 cells through the mitochondrial pathway.[Pubmed: 24173574]
    Ginsenosides, extracted from the traditional Chinese herb ginseng, are a series of novel natural anticancer products known for their favorable safety and efficacy profiles. The present study aimed to investigate the cytotoxicity of Ginsenoside Rf to human osteosarcoma cells and to explore the anticancer molecular mechanisms of Ginsenoside Rf.
    METHODS AND RESULTS:
    Five human osteosarcoma cell lines (MG-63, OS732, U-2OS, HOS and SAOS-2) were employed to investigate the cytotoxicity of Ginsenoside Rf by MTT and colony forming assays. After treatment with Ginsenoside Rf, MG-63 cells which were the most sensitive to Ginsenoside Rf, were subjected to flow cytometry to detect cell cycle distribution and apoptosis, and nuclear morphological changes were visualized by Hoechst 33258 staining. Caspase-3, -8 and -9 activities were also evaluated. The expression of cell cycle markers including cyclin B1 and Cdk1 was detected by RT-PCR and western blotting. The expression of apoptotic genes Bcl-2 and Bax and the release of cytochrome c were also examined by western blotting. Change in the mitochondrial membrane potential was observed by JC-1 staining in situ. Our results demonstrated that the cytotoxicity of Ginsenoside Rf to these human osteosarcoma cell lines was dose-dependent, and the MG-63 cells were the most sensitive to exposure to Ginsenoside Rf. Additionally, Ginsenoside Rf induced G2/M phase cell cycle arrest and apoptosis in MG-63 cells. Furthermore, we observed upregulation of Bax and downregulation of Bcl-2, Cdk1 and cyclin B1, the activation of caspase-3 and -9 and the release of cytochrome c in MG-63 cells following treatment with Ginsenoside Rf.
    CONCLUSIONS:
    Our findings demonstrated that Ginsenoside Rf induces G2/M phase cell cycle arrest and apoptosis in human osteosarcoma MG-63 cells through the mitochondrial pathway, suggesting that Ginsenoside Rf, as an effective natural product, may have a therapeutic effect on human osteosarcoma.
    Mol Pharmacol. 2002 Apr;61(4):928-35.
    Functional expression of a novel ginsenoside Rf binding protein from rat brain mRNA in Xenopus laevis oocytes.[Pubmed: 11901233]
    We have shown that Ginsenoside Rf (Rf) regulates voltage-dependent Ca(2+) channels through pertussis toxin (PTX)-sensitive G proteins in rat sensory neurons.
    METHODS AND RESULTS:
    These results suggest that Rf can act through a novel G protein-linked receptor in the nervous system. In the present study, we further examined the effect of Rf on G protein-coupled inwardly rectifying K(+) (GIRK) channels after coexpression with size-fractionated rat brain mRNA and GIRK1 and GIRK4 (GIRK1/4) channel cRNAs in Xenopus laevis oocytes using two-electrode voltage-clamp techniques. We found that Rf activated GIRK channel in a dose-dependent and reversible manner after coexpression with subfractions of rat brain mRNA and GIRK1/4 channel cRNAs. This Rf-evoked current was blocked by Ba(2+), a potassium channel blocker. The size of rat brain mRNA responding to Rf was about 6 to 7 kilobases. However, Rf did not evoke GIRK current after injection with this subfraction of rat brain mRNA or GIRK1/4 channel cRNAs alone. Other ginsenosides, such as Rb(1) and Rg(1), evoked only slight induction of GIRK currents after coexpression with the subfraction of rat brain mRNA and GIRK1/4 channel cRNAs. Acetylcholine and serotonin almost did not induce GIRK currents after coexpression with the subfraction of rat brain mRNA and GIRK1/4 channel cRNAs. Rf-evoked GIRK currents were not altered by PTX pretreatment but were suppressed by intracellularly injected guanosine-5'-(2-O-thio) diphosphate, a nonhydrolyzable GDP analog.
    CONCLUSIONS:
    These results indicate that Rf activates GIRK channel through an unidentified G protein-coupled receptor in rat brain and that this receptor can be cloned by the expression method demonstrated here.
    Life Sci. 2003 Jan 3;72(7):759-68.
    Ginsenoside Rf potentiates U-50,488H-induced analgesia and inhibits tolerance to its analgesia in mice.[Pubmed: 12479975]
    In the present study, the effect of Ginsenoside Rf (Rf), a trace component of Panax ginseng on U-50,488H (U50), a selective kappa opioid-induced analgesia and its tolerance to analgesia was studied using the mice tail-flick test. In addition, the possible mechanism by which Rf may affect U50-induced analgesia was investigated.
    METHODS AND RESULTS:
    Intraperitoneal administration of U50 (40 mg/kg) produced analgesia. Rf (10(-14)-10(-10) mg/kg) on co treatment dose-dependently potentiated the U50 (40 mg/kg)-induced analgesia. Rf (10(-12)-10(-2) mg/ml) did not alter the binding of [3H] naloxone, a opioid ligand and [3H]PN200-110, a dihydropyridine ligand to mice whole brain membrane. Twice daily administration of U50 (40 mg/kg) for six days induced tolerance to its analgesia. Chronic treatment (day 4-day 6) of Rf (10(-14)-10(-10) mg/kg) to U50-tolerant mice, dose-dependently inhibited the tolerance. The inhibition of tolerance to U50-induced analgesia by Rf was not altered by flumazenil (0.1 mg/kg), a benzodiazepine receptor antagonist and picrotoxin (1 mg/kg), a GABA(A)-gated chloride channel blocker on chronic treatment.
    CONCLUSIONS:
    In conclusion, these findings for the first time demonstrated that Ginsenoside Rf potentiates U50-induced analgesia, inhibits tolerance to its analgesia, and suggests that Rf affects U50-induced analgesia via non-opioid, non-dihydropyridine-sensitive Ca(+2) and non-benzodiazepine-GABA(A)ergic mechanisms in mice.
    Eur J Pharmacol. 2010 Aug 25;640(1-3):46-54.
    Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways.[Pubmed: 20580705]
    The herbal products baicalin, baicalein, chlorogenic acid, and Ginsenoside Rf have multiple pharmacological effects and are extensively used in alternative and/or complementary therapies. The present study investigated whether baicalin, baicalein, chlorogenic acid, and Ginsenoside Rf induced the expression of the cytochrome P450 3A4 (CYP3A4) and multi-drug resistance 1 (MDR1) genes through the pregnane X receptor and constitutive androstane receptor pathways.
    METHODS AND RESULTS:
    Real time PCR, western blotting, and a luminescent assay were used to assess the induction of gene expression and activity of CYP3A4 and MDR1 by the test compounds. The interactions of baicalein/chlorogenic acid/Ginsenoside Rf with constitutive androstane receptor and pregnane X receptor were evaluated using luciferase reporter and gel shift assays. Baicalein induced the expression of CYP3A4 and MDR1 mRNA by activating pregnane X receptor and constitutive androstane receptor. Chlorogenic acid and Ginsenoside Rf showed a relatively weak effect on CYP3A4 promoter activation only in HepG2 cells cotransfected with constitutive androstane receptor and demonstrated no effects on MDR1 via either the constitutive androstane receptor or pregnane X receptor pathway. Baicalin had no effect on either CYP3A4 or MDR1 gene expression.
    CONCLUSIONS:
    In conclusion, baicalein has the potential to up-regulate CYP3A4 and MDR1 through the direct activation of the constitutive androstane receptor and pregnane X receptor pathways. Chlorogenic acid and Ginsenoside Rf only induced constitutive androstane receptor-mediated CYP3A4 expression.
    Immunol Invest. 2016 Jul;45(5):439-49.
    Suppression of MAPKs/NF-κB Activation Induces Intestinal Anti-Inflammatory Action of Ginsenoside Rf in HT-29 and RAW264.7 Cells.[Pubmed: 27224660 ]
    This study investigated the intestinal anti-inflammatory action of Ginsenoside Rf in inflammatory bowel disease (IBD). IBD is a chronic inflammatory disease that affects the intestinal tract. It is associated with elevated levels of various inflammatory mediators, including interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), nitric oxide (NO), and reactive oxygen species (ROS). Ginsenosides, the main active constituents of ginseng, have been reported to exert potent therapeutic effects against diverse diseases. However, Ginsenoside Rf treatment for inflammation has not yet been examined.
    METHODS AND RESULTS:
    In this study, we evaluated the inhibitory effect of Ginsenoside Rf on the inflammatory mediators downstream of p38/NF-kB activation on TNF-α-stimulated intestinal epithelial cells (HT-29) and mouse macrophage cells (RAW264.7). Our results showed that Ginsenoside Rf significantly reduced the production of IL-1β, IL-6, TNF-α, NO, and ROS, which are most highly activated in IBD. In addition, Ginsenoside Rf significantly suppressed TNF-α/LPS-induced NF-κB transcriptional activity.
    CONCLUSIONS:
    These results suggest that Ginsenoside Rf contains a compound that has potent intestinal anti-inflammatory effects that could be used to treat diseases such as IBD.
    Brain Res. 1998 May 11;792(2):218-28.
    Ginsenoside Rf, a trace component of ginseng root, produces antinociception in mice.[Pubmed: 9593902]
    Ginseng root, a traditional oriental medicine, contains more than a dozen biologically active saponins called ginsenosides, including one present in only trace amounts called Ginsenoside Rf (Rf). Previously, we showed that Rf inhibits Ca2+ channels in mammalian sensory neurons through a mechanism requiring G-proteins, whereas a variety of other ginsenosides were relatively ineffective.
    METHODS AND RESULTS:
    Since inhibition of Ca2+ channels in sensory neurons contributes to antinociception by opioids, we tested for analgesic actions of Rf. We find dose-dependent antinociception by systemic administration of Rf in mice using two separate assays of tonic pain: in the acetic acid abdominal constriction test, the ED50 was 56+/-9 mg/kg, a concentration similar to those reported for aspirin and acetaminophen in the same assay; in the tonic phase of the biphasic formalin test, the ED50 was 129+/-32 mg/kg. Rf failed to affect nociception measured in three assays of acute pain: the acute phase of the formalin test, and the thermal (49 degrees C) tail-flick and increasing-temperature (3 degrees C/min) hot-plate tests. The simplest explanation is that Rf inhibits tonic pain without affecting acute pain, but other possibilities exist. Seeking a cellular explanation for the effect, we tested whether Rf suppresses Ca2+ channels on identified nociceptors. Inhibition was seen on large, but not small, nociceptors.
    CONCLUSIONS:
    This is inconsistent with a selective effect on tonic pain, so it seems unlikely that Ca2+ channel inhibition on primary sensory neurons can fully explain the behavioral antinociception we have demonstrated for Rf.
    Caohuoside E

    Catalog No: CFN95016
    CAS No: 174286-23-8
    Price: $318/5mg
    8-Hydroxypinoresinol diglucoside

    Catalog No: CFN95083
    CAS No: 112747-99-6
    Price: $318/5mg
    (E)-6-O-(p-coumaroyl)scandoside methyl ester

    Catalog No: CFN95192
    CAS No: 83946-90-1
    Price: $218/10mg
    Arisantetralone B

    Catalog No: CFN95211
    CAS No: 1161947-96-1
    Price: $413/5mg
    Rebaudioside F

    Catalog No: CFN95215
    CAS No: 438045-89-7
    Price: $268/5mg
    Perlolyrine

    Catalog No: CFN95291
    CAS No: 29700-20-7
    Price: $413/5mg
    Sibiricose A4

    Catalog No: CFN95298
    CAS No: 241125-73-5
    Price: $318/5mg
    3',5-Dihydroxy-4',6,7-trimethoxyflavanone

    Catalog No: CFN95316
    CAS No: 90850-99-0
    Price: $318/5mg
    Eschweilenol C

    Catalog No: CFN95363
    CAS No: 211371-02-7
    Price: $318/10mg
    Riligustilide

    Catalog No: CFN95457
    CAS No: 89354-45-0
    Price: $318/5mg